Die Evangelisch-Lutherische Diakonissenanstalt Flensburg, kurz DIAKO, ist ein evangelisches Unternehmen im Bereich der Wohlfahrtspflege mit Sitz in Flensburg. Mit fast 3300 Mitarbeitern ist die DIAKO der größte Arbeitgeber Flensburgs.

During the past decade, Ev. Luth. Diakonissenanstalt Flensburg conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ev. Luth. Diakonissenanstalt Flensburg" #1 sponsor was "Boston Scientific Corporation" with 3 trials, followed by "C. R. Bard" with 2 trials sponsored, "AGO Research GmbH" with 1 trials sponsored, "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 1 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ev. Luth. Diakonissenanstalt Flensburg" #1 collaborator was "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Australia New Zealand Gynaecological Oncology Group" with 1 trials as a collaborator, "Heart Center Leipzig - University Hospital" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Ev. Luth. Diakonissenanstalt Flensburg" are "Atherosclerosis of Native Arteries of the Extremities" (2 trials), "Atherosclerosis of Native Arteries of the Extremities, Unspecified" (1 trials), "Breast Cancer" (1 trials), "Chronic Heart Failure" (1 trials) and "Circulating Tumor Cells" (1 trials). Many other conditions were trialed in "Ev. Luth. Diakonissenanstalt Flensburg" in a lesser frequency.

Most popular intervention types in "Ev. Luth. Diakonissenanstalt Flensburg" are "Device" (6 trials), "Drug" (3 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bempedoic acid and/or its fixed-dose combination with ezetimibe" (1 trials), "Bevacizumab" (1 trials), "CRT-D implantation" (1 trials), "CRT-P implantation" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ev. Luth. Diakonissenanstalt Flensburg" are 8 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Ev. Luth. Diakonissenanstalt Flensburg". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Ev. Luth. Diakonissenanstalt Flensburg, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Ev. Luth. Diakonissenanstalt Flensburg, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".